Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 27; no. 11; pp. 1376 - 1383
• Main Authors: Rounbehler, Robert J, Berglund, Anders E, Gerke, Travis, Takhar, Mandeep M, Awasthi, Shivanshu, Li, Weimin, Davicioni, Elai, Erho, Nicholas G, Ross, Ashley E, Schaeffer, Edward M, Klein, Eric A, Karnes, R Jeffrey, Jenkins, Robert B, Cleveland, John L, Park, Jong Y, Yamoah, Kosj
• Format: Journal Article
• Language: English
• Published: United States 01.11.2018

We studied the utility of the tumor suppressor Tristetraprolin (TTP, ZFP36) as a clinically relevant biomarker of aggressive disease in prostate cancer patients after radical prostatectomy (RP). RNA expression was measured in an RP cohort of patients treated at Moffitt Cancer Center (MCC) and obtain...